On Nov 14, major Wall Street analysts update their ratings for $Corvus Pharmaceuticals (CRVS.US)$, with price targets ranging from $13 to $24.
Jefferies analyst Roger Song initiates coverage with a buy rating, and sets the target price at $13.
Mizuho Securities analyst Graig Suvannavejh maintains with a buy rating.
Oppenheimer analyst Jeff Jones maintains with a buy rating, and adjusts the target price from $8 to $14.
Ladenburg Thalmann analyst Aydin Huseynov maintains with a buy rating, and adjusts the target price from $21 to $24.
Furthermore, according to the comprehensive report, the opinions of $Corvus Pharmaceuticals (CRVS.US)$'s main analysts recently are as follows:
Anticipation is building for the upcoming report of Phase 1 interim data from soquelitinib in atopic dermatitis scheduled for December. The early data from the initial doses may furnish clinical proof of concept for the oral ITK inhibitor's potential in a wider range of inflammation and immunology applications.
Following the company's quarterly results, there is a positive outlook for the upcoming atopic dermatitis readout expected in December, illustrated by management's enthusiasm. Despite a constrained cash situation due to the level of clinical activity, the company reported having sufficient funds to continue operations into early 2026.
Here are the latest investment ratings and price targets for $Corvus Pharmaceuticals (CRVS.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
